The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Tumor-Targeting and Microenvironment-Responsive Smart Nanoparticles for Combination Therapy of Antiangiogenesis and Apoptosis
Abstract
Tumor microenvironment, such as the lowered tumor extracellular pH (pHe) and matrix metalloproteinase 2 (MMP2), has been extensively explored, which promotes the development of the microenvironment-responsive drug delivery system. Utilizing these unique features, an activatable cell-penetrating peptide (designated as dtACPP) that is dual-triggered by the lowered pHe and MMP2 has been constructed, and a smart nanoparticle system decorating with dtACPP has been successfully developed, which could dual-load gene drug and chemotherapeutics simultaneously. After systemic administration, dtACPP-modified nanoparticles possess passive tumor targetability via the enhanced permeability and retention effect. Then dtACPP would be activated to expose cell-penetrating peptide to drive the nanoparticles' internalization into the intratumoral cells. As angiogenesis and tumor cells might be mutually improved in tumor growth, so combining antiangiogenesis and apoptosis is meaningful for oncotherapy. Vascular endothelial growth factor (VEGF) is significant in angiogenesis, and anti-VEGF therapy could decrease blood vessel density and delay tumor growth obviously. Chemotherapy using doxorubicin (DOX) could kill off tumor cells efficiently. Here, utilizing dtACPP-modified nanoparticles to co-deliver plasmid expressing interfering RNA targeting VEGF (shVEGF) and DOX (designated as dtACPPD/shVEGF-DOX) results in effective shutdown of blood vessels and cell apoptosis within the tumor. On the premise of effective drug delivery, dtACPPD/shVEGF-DOX has demonstrated good tumor targetability, little side effects after systemic administration, and ideal antitumor efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Cited by
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery
Mo, R., & Gu, Z. (2016) · Materials Today · doi:10.1016/j.mattod.2015.11.025 · Cited by 381
Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y. (2013) · ACS Nano · doi:10.1021/nn4010796 · Cited by 379
Nonviral cancer gene therapy: Delivery cascade and vector nanoproperty integration
Zhou, Z., Liu, X., Zhu, D., Wang, Y., Zhang, Z., Zhou, X., Qiu, N., Chen, X., & Shen, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.021 · Cited by 379
Stimuli-sensitive nanopreparations for combination cancer therapy
Jhaveri, A., Deshpande, P., & Torchilin, V. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.002 · Cited by 334
Nanopreparations to overcome multidrug resistance in cancer
Patel, N. R., Pattni, B. S., Abouzeid, A. H., & Torchilin, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.004 · Cited by 333
Wang, J., Tang, W., Yang, M., Yin, Y., Li, H., Hu, F., Tang, L., Ma, X., Zhang, Y., & Wang, Y. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120784 · Cited by 317
Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy
Zhai, Y., Su, J., Ran, W., Zhang, P., Yin, Q., Zhang, Z., Yu, H., & Li, Y. (2017) · Theranostics · doi:10.7150/thno.20118 · Cited by 312
Jiang, T., Mo, R., Bellotti, A., Zhou, J., & Gu, Z. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201303222 · Cited by 298
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
Yang, G., Gong, H., Liu, T., Sun, X., Cheng, L., & Liu, Z. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.053 · Cited by 292
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Internal stimuli-responsive nanocarriers for drug delivery: Design strategies and applications
Liu, M., Du, H., Zhang, W., & Zhai, G. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2016.11.030 · Cited by 235
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
Physical‐, chemical‐, and biological‐responsive nanomedicine for cancer therapy
Liao, J., Jia, Y., Wu, Y., Shi, K., Yang, D., Li, P., & Qian, Z. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1581 · Cited by 67
Yang, Y., Meng, Y., Ye, J., Xia, X., Wang, H., Li, L., Dong, W., Jin, D., & Liu, Y. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.028 · Cited by 49
Self-citationZhang, B., Shi, W., Jiang, T., Wang, L., Mei, H., Lu, H., Hu, Y., & Pang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11546 · Cited by 41
Metadata
- Authors
- Huang, S., Shao, K., Liu, Y., Kuang, Y., Li, J., An, S., Guo, Y., Ma, H., & Jiang, C.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-03-12
- Volume
- 7
- Issue
- 3
- Pages
- 2860-2871
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2126991353
- Cited by
- 212
- References
- 3
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.